LVW Advisors LLC Boosts Stock Holdings in Amgen Inc. $AMGN

LVW Advisors LLC lifted its position in Amgen Inc. (NASDAQ:AMGN) by 44.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,124 shares of the medical research company’s stock after acquiring an additional 2,798 shares during the quarter. LVW Advisors LLC’s holdings in Amgen were worth $2,986,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Board of the Pension Protection Fund purchased a new position in Amgen during the fourth quarter worth about $26,000. Howard Hughes Medical Institute purchased a new stake in Amgen in the 2nd quarter valued at about $32,000. Olistico Wealth LLC purchased a new stake in Amgen in the 4th quarter valued at about $33,000. Cloud Capital Management LLC bought a new position in shares of Amgen during the 3rd quarter worth approximately $34,000. Finally, Saranac Partners Ltd bought a new position in shares of Amgen during the 3rd quarter worth approximately $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AMGN shares. HSBC reaffirmed a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. Mizuho lifted their price target on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Truist Financial boosted their price objective on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Finally, Royal Bank Of Canada raised their target price on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Performance

Shares of AMGN opened at $348.77 on Friday. The stock’s 50-day simple moving average is $362.59 and its 200 day simple moving average is $330.22. The stock has a market capitalization of $188.01 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the firm earned $5.31 EPS. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.